Trials with a site in Kyiv, Kyivska Oblast

This study wants to measure the long-term safety and how well it works of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase.

NCT03486873 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

To assess the how well it works and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

NCT06023589 · Official ClinicalTrials.gov record · AstraZeneca

This is a Phase III, international, multi-centre, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to measure the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.

NCT06307652 · Official ClinicalTrials.gov record · AstraZeneca

This is a study evaluating the how well it works and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to dummy treatment (placebo) plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

NCT06345729 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The Phase 1 study described herein will measure the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

NCT06619990 · Official ClinicalTrials.gov record · Xencor, Inc.

The study will measure the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the whether it is safe and how hard side effects are to live with of ocrelizumab. From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.

NCT06675955 · Official ClinicalTrials.gov record · Hoffmann-La Roche

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments.

NCT06677060 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

NCT06717347 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

International, Multicenter, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment and Event-driven study to assess how well it works, whether it is safe and how hard side effects are to live with of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

NCT06742723 · Official ClinicalTrials.gov record · AstraZeneca

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

NCT06841354 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to measure the long-term whether it is safe and how hard side effects are to live with of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

NCT06929273 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This study wants to measure the how well it works and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder

NCT06951698 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.

NCT06966700 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to measure the how well it works and safety of added on top of your current treatment KarXT for the treatment of mania in participants with Bipolar-I Disorder.

NCT07140913 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.

NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation.

NCT07190248 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This open-label, Phase I study will assess the whether it is safe and how hard side effects are to live with of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

NCT07201558 · Official ClinicalTrials.gov record · AstraZeneca

This is a randomly assigned, multicentre, multinational, neither you nor the study doctors know who gets the real treatment, integrated study to sompare the pharmacokinetics, how well it works, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

NCT07221734 · Official ClinicalTrials.gov record · mAbxience Research S.L.

This study wants to measure cardiovascular outcomes with orforglipron compared with dummy treatment (placebo) in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

NCT07241390 · Official ClinicalTrials.gov record · Eli Lilly and Company

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change.

NCT07252739 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.

NCT07359846 · Official ClinicalTrials.gov record · Generate Biomedicines

This study wants to measure the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

NCT07412704 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

The main purpose of this study is to measure the safety and effectiveness of LY4268989 when compared to dummy treatment (placebo) in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.

NCT07415044 · Official ClinicalTrials.gov record · Eli Lilly and Company

This is a phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant dummy treatment (placebo) plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant dummy treatment (placebo) plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.

NCT07431827 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.

NCT07476326 · Official ClinicalTrials.gov record · Biocon Biologics UK PLC

This is a Phase 1, first in human study to measure the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to dummy treatment (placebo) in participants with Rheumatoid Arthritis

NCT07533955 · Official ClinicalTrials.gov record · Jade Biosciences, Inc.

Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy.

NCT07554339 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to measure the how well it works, whether it is safe and how hard side effects are to live with of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from treatment trials.

NCT07624305 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to measure the how well it works, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

NCT07662109 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to measure the how well it works, safety, and tolerability of elecoglipron, compared with dummy treatment (placebo) in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

NCT07662135 · Official ClinicalTrials.gov record · AstraZeneca

The goal of this treatment study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also measure the safety of TRIV-573.

NCT07782333 · Official ClinicalTrials.gov record · Triveni Bio

Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of bladder cancer that has spread into the muscle layer of the bladder but has not spread to other distant parts of the body.

NCT07829783 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC